Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bio-Techne (TECH) Change in Receivables (2016 - 2025)

Bio-Techne has reported Change in Receivables over the past 17 years, most recently at -$941000.0 for Q4 2025.

  • Quarterly results put Change in Receivables at -$941000.0 for Q4 2025, down 251.04% from a year ago — trailing twelve months through Dec 2025 was -$36.5 million (down 283.3% YoY), and the annual figure for FY2025 was -$34.1 million, down 266.23%.
  • Change in Receivables for Q4 2025 was -$941000.0 at Bio-Techne, up from -$22.4 million in the prior quarter.
  • Over the last five years, Change in Receivables for TECH hit a ceiling of $51.6 million in Q1 2022 and a floor of -$28.9 million in Q2 2025.
  • Median Change in Receivables over the past 5 years was $357500.0 (2023), compared with a mean of $2.7 million.
  • Biggest five-year swings in Change in Receivables: tumbled 576.63% in 2022 and later surged 19380.43% in 2024.
  • Bio-Techne's Change in Receivables stood at $5.7 million in 2021, then grew by 3.5% to $5.9 million in 2022, then tumbled by 180.1% to -$4.7 million in 2023, then surged by 113.16% to $623000.0 in 2024, then crashed by 251.04% to -$941000.0 in 2025.
  • The last three reported values for Change in Receivables were -$941000.0 (Q4 2025), -$22.4 million (Q3 2025), and -$28.9 million (Q2 2025) per Business Quant data.